SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Genelux Q3 net loss widens on higher R&D costs

Genelux Q3 net loss widens on higher R&D costs Overview US biopharma firm's Q3 net loss widened, mis

ALXOCGONGNLX

Related stories